Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(40): 1998-2001
DOI: 10.1055/s-0031-1286379
DOI: 10.1055/s-0031-1286379
Endokrinologie & Diabetes | Commentary
Endokrinologie
© Georg Thieme Verlag KG Stuttgart · New York
Neue Entwicklungen bei Nebennierenerkrankungen
Recent advances in adrenal diseasesFurther Information
Publication History
Publication Date:
28 September 2011 (online)
![](https://www.thieme-connect.de/media/dmw/201140/lookinside/thumbnails/10.1055-s-0031-1286379-1.jpg)
Schlüsselwörter
Nebennierentumore - Inzidentalome - Nebenniereninsuffizienz
Keywords
adrenal tumors - incidentaloma - adrenal insufficiency
Literatur
- 1 Alkatib A A, Cosma M, Elamin M B, Erickson D, Swiglo B A, Erwin P J, Montori V M. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009; 94 3676-3681
- 2 Barron J. Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Pathol. 2010; 63 669-674
- 3 Betz M J, Degenhart C, Fischer E. et al . Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. Eur J Endocrinol. 2011; 165 301-306
- 4 Beuschlein F, Reincke M. [Every eighth case of hypertension originates in the adrenal gland. For whom is it worthwhile to screen for an endocrine cause?]. MMW Fortschr Med. 2010; 152 30-31
- 5 Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2010; 72 297-304
- 6 Bornstein S R. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009; 360 2328-2339
- 7 Brix D, Allolio B, Fenske W. et al . Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010; 58 609-615
- 8 Cawood T J, Hunt P J, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009; 161 513-527
- 9 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011; 96 1223-1236
- 10 Comino-Mendez I, Gracia-Aznarez F J, Schiavi F. et al . Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011; 43 663-667
- 11 de Bruin C, Feelders R A, Lamberts S W, Hofland L J. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome. Rev Endocr Metab Disord. 2009; 10 91-102
- 12 Eisenhofer G, Lenders J W, Timmers H. et al . Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011; 57 411-420
- 13 Fassnacht M, Johanssen S, Quinkler M. et al . Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115 243-250
- 14 Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011; 7 323-335
- 15 Fischer E, Beuschlein F, Reincke M. [Diagnosis of endocrinological hypertension: when to screen, and by which method?]. Dtsch Med Wochenschr. 2011; 136 537-540
- 16 Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord. 2011; 12 43-48
- 17 Funder J W, Reincke M. Aldosterone: a cardiovascular risk factor?. Biochim Biophys Acta. 2010; 1802 1188-1192
- 18 Johannsson G, Bergthorsdottir R, Nilsson A G, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet. Eur J Endocrinol. 2009; 161 119-130
- 19 Krug A W, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor?. Hypertension. 2008; 51 1252-1258
- 20 Lovas K, Husebe E S. Continuous subcutaneous hydrocortisone infusion in Addison`s disease. Eur J Endocrinol. 2007; 157 109-112
- 21 Nieman L K. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab. 2010; 95 4106-4113
- 22 Petrossians P, Thonnard A S, Beckers A. Medical treatment in Cushing’s syndrome: dopamine agonists and cabergoline. Neuroendocrinology. 2010; 92 Suppl 1 116-119
- 23 Qin Y, Yao L, King E E. et al . Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010; 42 229-233
- 24 Sbiera S, Schmull S, Assie G. et al . High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010; 95 (10) E161-71
- 25 Verma S, Vanryzin C, Sinaii N. et al . A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2010; 72 441-447
Dr. Matthias Gruber
Medizinische Klinik und Poliklinik III
Universitätsklinikum Carl
Gustav Carus
der Technischen Universität Dresden
Fetscherstraße 74
01307 Dresden
Email: Matthias.Gruber@uniklinikum-dresden.de